FAM218A

Across TCGA pan-cancer cohorts, FAM218A RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of FAM218A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where FAM218A RNA is repressed in tumor relative to normal tissue. In most cancer types FAM218A is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

THCA, COAD, and LUAD are the cancer types where FAM218A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM218A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.688	<.001	11	view →
COAD	All	III,IV	−0.514	<.001	11	view →
LUAD	All	III,IV	−0.702	<.001	10	view →
KICH	Male	All	−1.298	<.001	8	view →
READ	All	All	−0.725	<.001	7	view →
UCEC	All	II,III,IV	−1.152	<.001	6	view →
BRCA	All	III,IV	−0.651	<.001	6	view →
CHOL	Male	All	+0.843	<.001	4	view →
LUSC	Female	III,IV	−0.854	.007	3	view →
STAD	All	All	−0.423	.005	3	view →
BLCA	Male	IV	−0.875	.030	2	view →
KIRP	Male	All	−0.439	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

FAM218A–THCA

Open the THCA breakdown →